Cargando…

Axitinib in Combination With Toripalimab, a Humanized Immunoglobulin G(4) Monoclonal Antibody Against Programmed Cell Death-1, in Patients With Metastatic Mucosal Melanoma: An Open-Label Phase IB Trial

PURPOSE: Metastatic mucosal melanoma responds poorly to anti–programmed cell death-1 (PD-1) monotherapy. Vascular endothelial growth factor (VEGF) has been shown to play an important immunosuppressive role in the tumor microenvironment. The combination of VEGF inhibition and PD-1 blockade provides t...

Descripción completa

Detalles Bibliográficos
Autores principales:	Sheng, Xinan, Yan, Xieqiao, Chi, Zhihong, Si, Lu, Cui, Chuanliang, Tang, Bixia, Li, Siming, Mao, Lili, Lian, Bin, Wang, Xuan, Bai, Xue, Zhou, Li, Kong, Yan, Dai, Jie, Wang, Kai, Tang, Xiongwen, Zhou, Huaning, Wu, Hai, Feng, Hui, Yao, Sheng, Flaherty, Keith T., Guo, Jun
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	American Society of Clinical Oncology 2019
Materias:	Original Reports
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6839911/ https://www.ncbi.nlm.nih.gov/pubmed/31403867 http://dx.doi.org/10.1200/JCO.19.00210

Ejemplares similares

Toripalimab plus axitinib in patients with metastatic mucosal melanoma: 3-year survival update and biomarker analysis
por: Li, Siming, et al.
Publicado: (2022)

The Impact of Liver Metastasis on Anti-PD-1 Monoclonal Antibody Monotherapy in Advanced Melanoma: Analysis of Five Clinical Studies
por: Wang, Xuan, et al.
Publicado: (2020)

OrienX010, an oncolytic virus, in patients with unresectable stage IIIC–IV melanoma: a phase Ib study
por: Cui, ChuanLiang, et al.
Publicado: (2022)

Efficacy and safety of sorafenib versus sunitinib as first-line treatment in patients with metastatic renal cell carcinoma: largest single-center retrospective analysis
por: Sheng, Xinan, et al.
Publicado: (2016)

Proliferation Marker Ki67 as a Stratification Index of Adjuvant Chemotherapy for Resectable Mucosal Melanoma
por: Tang, Lirui, et al.
Publicado: (2022)

Association of NRAS Mutation With Clinical Outcomes of Anti-PD-1 Monotherapy in Advanced Melanoma: A Pooled Analysis of Four Asian Clinical Trials
por: Zhou, Li, et al.
Publicado: (2021)

Safety Profile of Immunotherapy Combined With Antiangiogenic Therapy in Patients With Melanoma: Analysis of Three Clinical Studies
por: Tian, Hui, et al.
Publicado: (2021)

Primary malignant melanoma of the esophagus: A retrospective analysis of clinical features, management, and survival of 76 patients
por: Wang, Xuan, et al.
Publicado: (2019)

Efficacy Evaluation of Imatinib for the Treatment of Melanoma: Evidence From a Retrospective Study
por: Wei, Xiaoting, et al.
Publicado: (2019)

A nomogram incorporating Ki67 to predict survival of acral melanoma
por: Du, Yu, et al.
Publicado: (2023)

A Functional Synonymous Variant in PDGFRA Is Associated with Better Survival in Acral Melanoma
por: Dai, Jie, et al.
Publicado: (2020)

Phase 1 trial of vorolanib (CM082) in combination with everolimus in patients with advanced clear-cell renal cell carcinoma
por: Sheng, Xinan, et al.
Publicado: (2020)

Chemotherapy combined with antiangiogenic drugs as salvage therapy in advanced melanoma patients progressing on PD-1 immunotherapy
por: Wang, Xuan, et al.
Publicado: (2020)

Safety, activity, and pharmacokinetics of camrelizumab in advanced Asian melanoma patients: a phase I study
por: Zhou, Li, et al.
Publicado: (2022)

Safety and Efficacy of Apatinib Combined with Temozolomide in Advanced Melanoma Patients after Conventional Treatment Failure()
por: Cui, ChuanLiang, et al.
Publicado: (2018)

HER2 Expression Associated with Clinical Characteristics and Prognosis of Urothelial Carcinoma in a Chinese Population
por: Zhou, Li, et al.
Publicado: (2023)

MicroRNA-23a-3p Inhibits Mucosal Melanoma Growth and Progression through Targeting Adenylate Cyclase 1 and Attenuating cAMP and MAPK Pathways
por: Ma, Meng, et al.
Publicado: (2019)

MicroRNA-23a-3p Inhibits Mucosal Melanoma Growth and Progression through Targeting Adenylate Cyclase 1 and Attenuating cAMP and MAPK Pathways: Erratum
por: Ma, Meng, et al.
Publicado: (2022)

Risk Models for Advanced Melanoma Patients Under Anti-PD-1 Monotherapy—Ad hoc Analyses of Pooled Data From Two Clinical Trials
por: Bai, Xue, et al.
Publicado: (2021)

Overall Survival of Patients With Unresectable or Metastatic BRAF V600-Mutant Acral/Cutaneous Melanoma Administered Dabrafenib Plus Trametinib: Long-Term Follow-Up of a Multicenter, Single-Arm Phase IIa Trial
por: Mao, Lili, et al.
Publicado: (2021)

Glycosylation-independent binding of monoclonal antibody toripalimab to FG loop of PD-1 for tumor immune checkpoint therapy
por: Liu, Hongchuan, et al.
Publicado: (2019)

Safety and clinical activity with an anti-PD-1 antibody JS001 in advanced melanoma or urologic cancer patients
por: Tang, Bixia, et al.
Publicado: (2019)

Molecular underpinnings of exceptional response in primary malignant melanoma of the esophagus to anti-PD-1 monotherapy
por: Dai, Jie, et al.
Publicado: (2023)

Phosphorylation of mTOR and S6RP predicts the efficacy of everolimus in patients with metastatic renal cell carcinoma
por: Li, Siming, et al.
Publicado: (2014)

Regorafenib plus toripalimab in patients with metastatic colorectal cancer: a phase Ib/II clinical trial and gut microbiome analysis
por: Wang, Feng, et al.
Publicado: (2021)

Severe cumulative skin toxicity during toripalimab combined with vemurafenib following toripalimab alone
por: Zhou, Hong, et al.
Publicado: (2023)

Clinical presentation, histology, and prognoses of malignant melanoma in ethnic Chinese: A study of 522 consecutive cases
por: Chi, Zhihong, et al.
Publicado: (2011)

Surgical Outcomes of Vaginal or Cervical Melanoma
por: Tian, Hui, et al.
Publicado: (2022)

The Clinicopathological and Survival Profiles Comparison Across Primary Sites in Acral Melanoma
por: Wei, Xiaoting, et al.
Publicado: (2020)

Toripalimab in advanced biliary tract cancer
por: Li, Wei, et al.
Publicado: (2022)

miR-let-7b and miR-let-7c suppress tumourigenesis of human mucosal melanoma and enhance the sensitivity to chemotherapy
por: Tang, Huan, et al.
Publicado: (2019)

Anti-GAD65 Antibody-Associated Autoimmune Encephalitis With Predominant Cerebellar Involvement Following Toripalimab Treatment: A Case Report of a Novel irAE of Toripalimab
por: Zhou, Huanyu, et al.
Publicado: (2022)

Phase Ib dose-finding study of axitinib plus pembrolizumab in treatment-naïve patients with advanced renal cell carcinoma
por: Atkins, Michael B, et al.
Publicado: (2015)

A phase I study of toripalimab, an anti‐PD‐1 antibody, in patients with refractory malignant solid tumors
por: Wei, Xiao‐Li, et al.
Publicado: (2020)

Safety and efficacy of Pucotenlimab (HX008) - a humanized immunoglobulin G4 monoclonal antibody in patients with locally advanced or metastatic melanoma: a single-arm, multicenter, phase II study
por: Cui, Chuanliang, et al.
Publicado: (2023)

Phase Ib study of CP-868,596, a PDGFR inhibitor, combined with docetaxel with or without axitinib, a VEGFR inhibitor
por: Michael, M, et al.
Publicado: (2010)

A Phase Ib Study of Axitinib in Combination with Crizotinib in Patients with Metastatic Renal Cell Cancer or Other Advanced Solid Tumors
por: Michaelson, M. Dror, et al.
Publicado: (2019)

Study protocol for an open-label, single-arm, phase Ib/II study of combination of toripalimab, nab-paclitaxel, and gemcitabine as the first-line treatment for patients with unresectable pancreatic ductal adenocarcinoma
por: Shui, Lin, et al.
Publicado: (2020)

Systemic Immune-Inflammation Index and Circulating T-Cell Immune Index Predict Outcomes in High-Risk Acral Melanoma Patients Treated with High-Dose Interferon
por: Yu, Jiayi, et al.
Publicado: (2017)

Inhibition of Axitinib on Buspirone Metabolism in vitro and in vivo
por: Zhang, Bo-Wen, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_bmkbticgpsneoungof1qf2nh1a